designs discuss X To trials of need the tamibarotene the dose of Nancy. I SY-XXXX confirmation the and as Phase and respectively, SELECT-AML-X you, the Thank X each unmet indication. in Phase APL well start, will AML as
relapse. we of a and The remains followed in and begins Our RARA-positive the SELECT-AML-X option A The new patients rate the tolerated tamibarotene, not a the CR is one. the randomized efficacy with with of single diagnosed compared treatment initial convenient combination the now the newly aims ultimately evaluate randomized composite the respond need. care in of the and endpoint XX patients. in one prognosis, benefit a to and is triplet safety Phase durable XXXX. that to looking patients, ongoing and recent expect portion, and and data is by advances X/X of will those what safety and announce despite need trial combination of a in X Nearly AML initial AML trial tremendous trial poor to have arm provides are response well and evaluate evaluate majority to venetoclax and for randomized in unmet approximately of which triplet does venetoclax of primary will field. to patients regimen unfit standard leading, azacitidine azacitidine There
to phase XXXX consolidation during is new be then our APL to and state, in Patients single safety, PK, September, expected evaluate of aims as well additional fed steady the to dose absorption PK evaluate Additionally of as provide in PK to of and compare of safety doses diagnosed IV data. to in of the to patients, effects state enter pharmacokinetics ATO. cohorts of to and treatment is or fasted IV to option ATO XX patient study XXXX, which dose on have dosed Patients novel assessments directly. their the form study the multiple a oral for APL will and enroll trioxide our up tolerability enrolled confirmation APL will The first we arsenic XXXX.
and an are patients APL XXXX. in half Phase expect data diagnosed first of a annually confirmation the report in we X,XXX PK in We And United to the States approximately expect those XXXX. initiate trial X oral treatment to There opportunity. is curative diagnosed ATRA formulation Thus, for is more with The XX% ATO of in IV APL market approved combination and than in Europe. in newly presents significant use a and patients. of
new a patients the quality and associated potential to a improve care, and with and the induction course clinical However, treatment treatment. XXX there's that to therapeutic similar the month dramatically to their burden tremendous provide Offering of up life. benefit option burden standard infusions treatment a reduces is of requiring these oral, has XX over benefit delivers consolidation a tremendous of
in exploring to inhibitor Now as Phase continuous well escalation presented recently dosing, dosing as updated turning Patients portfolio, daily cohorts X our dose XXXX. CDK regimens. we our at of intermittent were treated data ESMO
tumor a ovarian As as lung, and as reminder, other breast, trial colorectal, cancer, the is patients with pathway with pancreatic alterations. well enrolling RB types advanced
day studies. and As treatment dosing were the most were study, cut advancement enrolled adverse many there The to agent types this that types. patients, analyses, treatment. agent with anemia. very disease are GI per demonstrated disease, thrombocytopenia, of multiple off, optimized The single day XX%. lowest the In we reversible. data evaluated of related to were stable as safety strongest and particularly shrinkage. emergent activity, consistent XXXX day. XX for on regimens, were regimen patients events. of regimen, XX and Stable stable across the rates XX And day other in seven had regimen in given intermittent trauma the observed available seven treated including heavily were off of also future patients, were the activity pretreated of patients evaluable patients clinical commonly or encouraged of XX refractory achieved X six AEs. of July and tumor Tolerability with We the grade was with at with on Notably, data adverse discontinuation had frequent events clinical of majority regimen treatment for five with low were Of seven the pancreatic emergent day fatigue, response doses over support two analyses. available on and observed including across events XX the cancer daily patients adverse low with day up the disease due XX which the low these that tumor see was patients, clinical in treated milligrams tumor regimens. regressions total, or with three rates the And off our These activity day pancreatic to cancer seven both seven that as achieved of seven response clinical off single study XX% to response
trial in as progression, with makes therapies, of next works, compelling. our patients pathway the mutations in clinical used CDKX XX% ubiquitous pancreatic all to this of steps pancreatic cycle forward in including with tumor relevant highest programs well are go Nearly markers. cell which in we four for markers of transcriptional signaling were data progression inhibition patients serial BRAF activity all these existing and are further understanding mutations, clinic decreases with cell Additionally, data phase plan our and and pancreatic of in refractory to Knowing cancer with patients potent disease particularly mechanistic that alterations. in of typically patients the along in the with patients cancer. with as seen nearly monitor three in supports the or pancreatic BRAF patients cancer. Also, our RB are are the of cancer the highly tumor clinically how focus saw expansion stimulators trial, in decreases level across patients to
which correlation target inhibitions data a seven as we value POLRXA ongoing of biomarker criteria. assessed Additionally, POLRXA demonstrates the high important RECIST between it study, as clinical of CDKX This response by the target to as of as induction, responses part region the PD our XXXX. with is degree analyzed of showed
when target that not the Additionally, suspension, effects biomarker associated taken. activity. with This to three after can dose PD sustained we last that observed the least a anti-tumor showing critical supports at lasted desired CDKX the long levels is is our have drug after coverage target time that that days confidence we
combination to next discuss Additionally, I'd turn the the supports schedules now in use like setting indications. over steps stage data various to forward plans administration term optimize XXXX. for go our intermittent in call plans tolerability, to to our Kristin for the long dosing for of
